Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 ...

5 days ago · During the last three months, 4 analysts shared their evaluations of Keros Therapeutics (NASDAQ:KROS), revealing diverse outlooks from bullish to bearish. In the table …

CouponFollow Extension

$100
OFF

Keros Therapeutics Inc. - MarketWatch

1 day from now

Nov 6, 2024 · Keros Therapeutics started at buy with $100 stock price target at Truist Oct. 18, 2022 at 7:23 a.m. ET by Tomi Kilgore Keros Therapeutics sets IPO terms, expects to raise up …

marketwatch.com

13%
OFF

Keros Therapeutics - KROS - Stock Price Today - Zacks

1 day from now

5 days ago · After-Market: $55.85 -0.07 (-0.13%) 7:58 PM ET. Add to portfolio. Zacks Rank: This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 …

zacks.com

$530.68
OFF

Keros Therapeutics Statistics - Stock Analysis

1 day from now

Nov 6, 2024 · The company has $530.68 million in cash and $19.29 million in debt, giving a net cash position of $511.40 million or $12.62 per share. Cash & Cash Equivalents. 530.68M. …

stockanalysis.com

$5.28
OFF

Keros Therapeutics (KROS) Stock Price, News & Analysis

1 day from now

6 days ago · Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($5.28) to ($5.76) per share. The P/E ratio of Keros Therapeutics is -10.73, which means that …

marketbeat.com

$43
OFF

TG Therapeutics Stock: A Deep Dive Into Analyst Perspectives

1 day from now

2 days ago · In the assessment of 12-month price targets, analysts unveil insights for TG Therapeutics, presenting an average target of $43.8, a high estimate of $55.00, and a low …

nasdaq.com

FAQs about Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 ... Coupon?

Should I buy Keros Therapeutics (Kros)?

According to 7 Wall Street research analysts in the last year, you should buy Keros Therapeutics (KROS) shares. The consensus among these analysts is to buy KROS. You can view the KROS analyst ratings or top-rated stocks. ...

How much is Keros Therapeutics worth?

Keros Therapeutics has set terms of its initial public offering, in which it expects to raise up to $80 million, and be valued at about $291 million. The biopharmaceutical company, which is developing treatments for hemat... Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. ...

Who is Keros Therapeutics?

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA. ...

How many research reports have been made about Keros Therapeutics?

In the past 90 days, there have been 3 research reports published about Keros Therapeutics. Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. ...

Who owns Keros Therapeutics stock?

The top institutional owners of Keros Therapeutics stock include BlackRock Inc. (5.88%), Braidwell LP (3.86%), State Street Corp (3.42%), Candriam S.C.A. (2.44%), and Eventide Asset Management LLC (1.96%). Keros Therapeutics' stock is owned by a variety of institutional and retail investors. ...

Which ETF has the most Keros Therapeutics stock?

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ALPS Medical Breakthroughs ETF (SBIO) have the largest holdings of Keros Therapeutics (NASDAQ:KROS) stock in their portfolios. BNY Mellon Innovators ETF (BKIV) also holds Keros Therapeutics stock. What other stocks do shareholders of Keros Therapeutics own? ...